
Intra-Cellular Therapies ITCI
Geschäftsbericht 2024
hinzugefügt 21.02.2025
Intra-Cellular Therapies EV 2011-2026 | ITCI
EV Jährlich Intra-Cellular Therapies
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.2 B | 6.76 B | 4.59 B | 4.23 B | 2.24 B | 1.22 B | 624 M | 766 M | 541 M | 1.3 B | 506 M | 293 M | -12.8 M | -13.7 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 13.2 B | -13.7 M | 2.59 B |
EV anderer Aktien in der Pharmaeinzelhändler
| Name | EV | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
1.82 B | - | 2.43 % | $ 254 M | ||
|
AbCellera Biologics
ABCL
|
1.22 B | $ 3.55 | -0.28 % | $ 1.06 B | ||
|
Acorda Therapeutics
ACOR
|
-13.2 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
24 M | - | 4.01 % | $ 150 M | ||
|
Advaxis
ADXS
|
-3.02 M | - | -9.65 % | $ 45.9 M | ||
|
AC Immune SA
ACIU
|
82.4 M | $ 3.26 | 4.15 % | $ 229 M | ||
|
I-Mab
IMAB
|
8.28 B | - | - | $ 866 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-23.2 M | - | - | $ 1.01 B | ||
|
AgeX Therapeutics
AGE
|
6.28 M | - | -10.17 % | $ 12.2 K | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.95 B | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
525 M | - | -13.47 % | $ 169 M | ||
|
Albireo Pharma
ALBO
|
417 M | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
33.1 M | - | 10.36 % | $ 9.8 M | ||
|
Aptorum Group Limited
APM
|
9.45 M | $ 0.79 | 0.05 % | $ 4.31 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
3.41 B | - | -1.52 % | $ 24.7 M | ||
|
ADC Therapeutics SA
ADCT
|
114 M | $ 4.14 | -1.9 % | $ 105 M | ||
|
Midatech Pharma plc
MTP
|
4.79 M | - | -18.52 % | $ 27.3 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
43.4 M | $ 6.55 | -1.16 % | $ 179 M | ||
|
argenx SE
ARGX
|
-796 M | $ 711.17 | 1.12 % | $ 25 B | ||
|
Alterity Therapeutics Limited
ATHE
|
-28.9 M | $ 3.43 | -4.99 % | $ 8.25 B | ||
|
Adverum Biotechnologies
ADVM
|
125 M | - | - | $ 86.2 M | ||
|
Ascendis Pharma A/S
ASND
|
849 M | $ 230.22 | -0.35 % | $ 5 B | ||
|
BioCardia
BCDA
|
12.4 M | $ 1.3 | 1.97 % | $ 27.5 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-9.16 M | - | - | $ 26.5 M | ||
|
Applied Molecular Transport
AMTI
|
7.6 M | - | - | $ 10.1 M | ||
|
Atea Pharmaceuticals
AVIR
|
370 M | $ 6.12 | 1.16 % | $ 499 M | ||
|
Институт стволовых клеток человека
ISKJ
|
14.1 M | - | - | - | ||
|
Akero Therapeutics
AKRO
|
2.99 B | - | - | $ 3.67 B | ||
|
Athersys
ATHX
|
-37.4 M | - | 3.77 % | $ 22.4 M | ||
|
Akouos
AKUS
|
95.1 M | - | 0.23 % | $ 488 M | ||
|
Acer Therapeutics
ACER
|
38.2 M | - | 2.71 % | $ 14 M | ||
|
ARCA biopharma
ABIO
|
436 M | - | 1052.0 % | $ 415 M | ||
|
Allena Pharmaceuticals
ALNA
|
-14.1 M | - | 3.16 % | $ 1.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
647 M | $ 3.43 | -4.19 % | $ 7.46 B | ||
|
Aeterna Zentaris
AEZS
|
5.52 M | - | 5.93 % | $ 314 M | ||
|
Catalyst Biosciences
CBIO
|
986 M | $ 11.3 | -2.46 % | $ 1.01 B | ||
|
AlloVir
ALVR
|
-64.1 M | - | 4.14 % | $ 49.1 M | ||
|
Anika Therapeutics
ANIK
|
300 M | $ 14.59 | 1.6 % | $ 214 M | ||
|
Aptinyx
APTX
|
-18.3 M | - | -39.0 % | $ 4.57 M | ||
|
Aptose Biosciences
APTO
|
10.8 M | - | -45.71 % | $ 1.2 M | ||
|
CNS Pharmaceuticals
CNSP
|
-3.42 M | $ 2.4 | -2.04 % | $ 917 K | ||
|
AVEO Pharmaceuticals
AVEO
|
86.9 M | - | - | $ 521 M | ||
|
Ayala Pharmaceuticals
AYLA
|
5.32 M | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
-15.2 M | $ 2.63 | -0.57 % | $ 16.5 M | ||
|
Avenue Therapeutics
ATXI
|
-1.23 M | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
1.11 B | $ 1.52 | 0.33 % | $ 388 M | ||
|
BioNTech SE
BNTX
|
-4.91 B | $ 94.73 | 4.62 % | $ 27.2 B | ||
|
Athira Pharma
ATHA
|
-18.3 M | - | - | $ 269 M | ||
|
CureVac N.V.
CVAC
|
3.19 B | - | - | $ 867 M | ||
|
Aravive
ARAV
|
58.2 M | - | -13.39 % | $ 1.45 M |